Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19.
COVID-19
HIV
MSM
STIs
sexual behaviour
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
26
05
2023
accepted:
26
07
2023
medline:
11
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
Despite decreased numbers of sexual partners, the COVID-19 pandemic had limited impact on the prevalence of attending private sex parties, traveling for sex within Switzerland, and practicing chemsex in men with HIV who have sex with men. COVID-19 risk perception was low, and STI-diagnosis incidence rates remained stable over time.
Identifiants
pubmed: 37564741
doi: 10.1093/ofid/ofad399
pii: ofad399
pmc: PMC10411039
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad399Investigateurs
I Abela
(I)
K Aebi-Popp
(K)
A Anagnostopoulos
(A)
M Battegay
(M)
E Bernasconi
(E)
D L Braun
(DL)
H C Bucher
(HC)
A Calmy
(A)
M Cavassini
(M)
A Ciuffi
(A)
G Dollenmaier
(G)
M Egger
(M)
L Elzi
(L)
J Fehr
(J)
J Fellay
(J)
H Furrer
(H)
C A Fux
(CA)
H F Günthard
(HF)
A Hachfeld
(A)
D Haerry
(D)
B Hasse
(B)
H H Hirsch
(HH)
M Hoffmann
(M)
I Hösli
(I)
M Huber
(M)
D Jackson-Perry
(D)
C R Kahlert
(CR)
L Kaiser
(L)
O Keiser
(O)
T Klimkait
(T)
R D Kouyos
(RD)
H Kovari
(H)
K Kusejko
(K)
N Labhardt
(N)
K Leuzinger
(K)
B Martinez de Tejada
(B)
C Marzolini
(C)
K J Metzner
(KJ)
N Müller
(N)
J Nemeth
(J)
D Nicca
(D)
J Notter
(J)
P Paioni
(P)
G Pantaleo
(G)
M Perreau
(M)
A Rauch
(A)
L Salazar-Vizcaya
(L)
P Schmid
(P)
R Speck
(R)
M Stöckle
(M)
P Tarr
(P)
A Trkola
(A)
G Wandeler
(G)
M Weisser
(M)
S Yerly
(S)
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. None of the authors has declared a possible conflict of interest related to this study. AH's institution has received travel grants, congress and advisory fees from MSD, Viiv and Gilead, unrelated to this work. AR reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, Pfizer and Moderna, and an investigator initiated trial (IIT) grant from Gilead Sciences. All remuneration went to his home institution and not to AR personally, and all remuneration was provided outside the submitted work. AC reported unrestricted Education grants from Gilead Sciences, MSD and ViiV; research grant from MSD. DLB reported honoraria payed to himself for advisory boards from the companies Gilead, MSD and ViiV outside of the submitted work. EB's institution has received travel grants and advisory fees from MSD, ViiV Healthcare, Gilead Sciences, Pfizer, Astra Zeneca, Ely Lilly, and Moderna, unrelated to this work. MC's institution received research grants and expert opinion honoraria from Gilead, MSD and Viiv outside of the submitted work. RDK reports research grants from Gilead Sciences, unrelated to this work.
Références
Open Forum Infect Dis. 2022 Nov 16;9(12):ofac592
pubmed: 36504700
Trop Med Int Health. 2010 Mar;15(3):362-81
pubmed: 20409291
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):288-296
pubmed: 33230027
HIV Med. 2023 Feb;24(2):212-223
pubmed: 36226479
J Infect Dis. 2023 Feb 1;227(3):407-411
pubmed: 36408629
Int J Epidemiol. 2022 Feb 18;51(1):33-34j
pubmed: 34363666
Behav Res Methods. 2015 Dec;47(4):1237-1259
pubmed: 25410404
Sex Transm Infect. 2021 Nov;97(7):521-524
pubmed: 33462118
BMC Med Res Methodol. 2017 Aug 17;17(1):125
pubmed: 28818053
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):153-156
pubmed: 33433122
Swiss Med Wkly. 2022 Jun 27;152:w30192
pubmed: 35758418